DT
Therapeutic Areas
Medigene Pipeline
| Drug | Indication | Phase |
|---|---|---|
| MDG1011 | Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Multiple Myeloma (MM) | Phase I/II |
| MDG1021 | Solid Tumors | Preclinical |
| TCR Library Program | Various Solid Tumors | Discovery |
Leadership Team at Medigene
PD
Prof. Dr. Dolores J. Schendel
Chief Executive Officer & Chief Scientific Officer
DS
Dr. Selwyn Ho
Chief Financial Officer
DK
Dr. Kirsten Richter
Chief Development Officer
DK
Dr. Kai Pinkernell
Chief Medical Officer
DK
Dr. Kristina Rübsamen-Schaeff
Chairperson of the Supervisory Board